| Medical and Health Sciences | 2021-2025 | 52 | PK 1 | 99.99 |
| Economics and Finance | 2021-2025 | 855 | PK 8 | 96.55 |
| Surgery | Lifetime | 281 | PK 1 | 99.76 |
| Cardiology and Cardiovascular Medicine | Lifetime | 334 | PK 1 | 99.57 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 678 | PK 1 | 97.73 |
| Geriatrics and Gerontology | Lifetime | 522 | PK 1 | 76.29 |
| Surgery | 2021-2025 | 23 | PK 1 | 99.86 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 44 | PK 1 | 99.83 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 79 | PK 1 | 98.88 |
| Health | 2021-2025 | 75 | PK 1 | 98.11 |
| Epidemiology | 2021-2025 | 303 | PK 1 | 97.51 |
| General Health Professions | 2021-2025 | 426 | PK 2 | 96.68 |
| Econometrics and Quantitative Economics | 2021-2025 | 605 | PK 8 | 96.44 |
| Public, Environmental and Occupational Health | 2021-2025 | 603 | PK 2 | 94.29 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 376 | PK 2 | 92.47 |
| Medical Physiology | 2021-2025 | 958 | PK 1 | 83.56 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 172 | PK 1 | 99.42 |
| Lipoproteins and Cardiovascular Health | Lifetime | 82 | PK 1 | 99.53 |
| Pharmaceutical Economics and Policy | Lifetime | 52 | PK 1 | 98.83 |
| Cardiac Health and Mental Health | Lifetime | 88 | PK 1 | 99.04 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 151 | PK 1 | 99.36 |
| Cardiovascular Health and Risk Factors | Lifetime | 76 | PK 1 | 98.69 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 636 | PK 2 | 98.69 |
| Blood Pressure and Hypertension Studies | Lifetime | 316 | PK 1 | 98.97 |
| Cancer, Lipids, and Metabolism | Lifetime | 394 | PK 1 | 98.44 |
| Acute Myocardial Infarction Research | Lifetime | 392 | PK 1 | 98.77 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 403 | PK 1 | 98.18 |
| Cardiovascular Health and Disease Prevention | Lifetime | 727 | PK 1 | 96.92 |
| Cardiovascular Disease and Adiposity | Lifetime | 801 | PK 1 | 96.30 |
| Medication Adherence and Compliance | Lifetime | 422 | PK 1 | 94.46 |
| Global Public Health Policies and Epidemiology | Lifetime | 631 | PK 3 | 93.90 |
| Lipid metabolism and disorders | Lifetime | 545 | PK 1 | 94.61 |
| Biomarkers in Disease Mechanisms | Lifetime | 501 | PK 1 | 86.65 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 685 | PK 1 | 88.36 |
| Aortic Thrombus and Embolism | Lifetime | 229 | PK 1 | 84.75 |
| Nursing Roles and Practices | Lifetime | 938 | PK 1 | 82.63 |
| Cardiac Health and Mental Health | 2021-2025 | 1 | PK 1 | 99.79 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 20 | PK 1 | 99.52 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 10 | PK 1 | 99.73 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 10 | PK 1 | 99.77 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 6 | PK 1 | 99.43 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 40 | PK 1 | 99.07 |
| Acute Myocardial Infarction Research | 2021-2025 | 48 | PK 1 | 99.05 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 41 | PK 1 | 97.38 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 38 | PK 1 | 98.65 |
| Health disparities and outcomes | 2021-2025 | 90 | PK 1 | 97.89 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 31 | PK 1 | 96.85 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 10 | PK 1 | 96.29 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 208 | PK 1 | 98.38 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 255 | PK 1 | 93.08 |
| Diabetes Treatment and Management | 2021-2025 | 390 | PK 2 | 95.79 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 206 | PK 1 | 93.12 |
| COVID-19 and healthcare impacts | 2021-2025 | 697 | PK 3 | 91.15 |
| Cardiac, Anesthesia and Surgical Outcomes | 2021-2025 | 815 | PK 1 | 93.76 |
| Heart Failure Treatment and Management | 2021-2025 | 532 | PK 1 | 93.62 |
| Pharmaceutical Economics and Policy | 2021-2025 | 149 | PK 1 | 91.02 |
| Lipid metabolism and disorders | 2021-2025 | 104 | PK 1 | 89.03 |
| Global Health Care Issues | 2021-2025 | 376 | PK 3 | 87.00 |
| Climate Change and Health Impacts | 2021-2025 | 949 | PK 3 | 87.63 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 394 | PK 1 | 86.20 |
| Medication Adherence and Compliance | 2021-2025 | 500 | PK 4 | 78.62 |
| Primary Care and Health Outcomes | 2021-2025 | 842 | PK 2 | 79.48 |
| Fatty Acid Research and Health | 2021-2025 | 533 | PK 4 | 77.44 |
| Employment and Welfare Studies | 2021-2025 | 981 | PK 1 | 77.59 |
| Potassium and Related Disorders | 2021-2025 | 294 | PK 1 | 76.94 |
| Diabetes Management and Education | 2021-2025 | 899 | PK 4 | 73.81 |
| Healthcare cost, quality, practices | 2021-2025 | 970 | PK 1 | 68.83 |
| Apelin-related biomedical research | 2021-2025 | 581 | PK 4 | 44.28 |
| Medical Coding and Health Information | 2021-2025 | 297 | PK 1 | 39.19 |
| Pharmaceutical industry and healthcare | 2021-2025 | 586 | PK 8 | 34.21 |
| Global Health and Epidemiology | 2021-2025 | 248 | PK 7 | 28.63 |
